Effects of combined insulin-sulfonylurea therapy in type II patients - PubMed (original) (raw)
Clinical Trial
Effects of combined insulin-sulfonylurea therapy in type II patients
M S Lewitt et al. Diabetes Care. 1989 Jun.
Abstract
We conducted a double-blind crossover study to determine which patient characteristics best predict a beneficial response to combined insulin-glyburide therapy. Glyburide (15 mg/day) or placebo was added to the treatment regimen of 31 insulin-treated type II (non-insulin-dependent) diabetic subjects. During glyburide therapy, there was a significant improvement in glycemic control with a reduction in glycosylated hemoglobin from 9.9 +/- 1.3 to 9.1 +/- 1.3% (P less than .001). Patients who responded had higher fasting C-peptide levels (P less than .001) and shorter durations of insulin therapy (P less than .01) than those who did not respond. Glyburide withdrawal was associated with a greater than expected deterioration in glycemic control. Patients on insulin therapy for greater than 8 yr are unlikely to benefit significantly from the addition of glyburide to their treatment regimen.
Comment in
- Stability of stored chemstrip bG.
Mezitis NH, Heshka S, Zappulla D, Pi-Sunyer FX. Mezitis NH, et al. Diabetes Care. 1990 Feb;13(2):179-80. doi: 10.2337/diacare.13.2.179. Diabetes Care. 1990. PMID: 2351017 No abstract available.
Similar articles
- Concomitant insulin and sulfonylurea therapy in patients with type II diabetes. Effects on glucoregulation and lipid metabolism.
Osei K, O'Dorisio TM, Falko JM. Osei K, et al. Am J Med. 1984 Dec;77(6):1002-9. doi: 10.1016/0002-9343(84)90179-7. Am J Med. 1984. PMID: 6439036 Clinical Trial. - Combination insulin/glyburide therapy in type II diabetes mellitus. Effects on lipoprotein metabolism and glucoregulation.
Falko JM, Osei K. Falko JM, et al. Am J Med. 1985 Sep 20;79(3B):92-101. doi: 10.1016/s0002-9343(85)80014-0. Am J Med. 1985. PMID: 3931467 Clinical Trial. - Serum C-peptide levels determine glycemic responses in type II diabetic patients treated with combined insulin and sulfonylurea agent.
Osei K, Falko JM. Osei K, et al. Am J Med Sci. 1985 Apr;289(4):148-53. doi: 10.1097/00000441-198504000-00004. Am J Med Sci. 1985. PMID: 3920907 - Transient effect of the combination of insulin and sulfonylurea (glibenclamide) on glycemic control in non-insulin dependent diabetics poorly controlled with insulin alone.
Groop L, Harno K, Nikkilä EA, Pelkonen R, Tolppanen EM. Groop L, et al. Acta Med Scand. 1985;217(1):33-9. doi: 10.1111/j.0954-6820.1985.tb01631.x. Acta Med Scand. 1985. PMID: 3919531 Clinical Trial. - New modalities in diabetes treatment.
Lawrence AM, Abraira C. Lawrence AM, et al. Am J Med. 1988 Nov 28;85(5A):153-8. doi: 10.1016/0002-9343(88)90409-3. Am J Med. 1988. PMID: 3143264 Review.
Cited by
- Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus.
Lin C, Cai X, Yang W, Lv F, Nie L, Ji L. Lin C, et al. BMC Med. 2020 Nov 16;18(1):322. doi: 10.1186/s12916-020-01787-4. BMC Med. 2020. PMID: 33190640 Free PMC article. - Insulin Monotherapy Versus Insulin Combined with Other Glucose-Lowering Agents in Type 2 Diabetes: A Narrative Review.
Abdi H, Azizi F, Amouzegar A. Abdi H, et al. Int J Endocrinol Metab. 2018 Apr 21;16(2):e65600. doi: 10.5812/ijem.65600. eCollection 2018 Apr. Int J Endocrinol Metab. 2018. PMID: 30008760 Free PMC article. Review. - Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.
Vos RC, van Avendonk MJ, Jansen H, Goudswaard AN, van den Donk M, Gorter K, Kerssen A, Rutten GE. Vos RC, et al. Cochrane Database Syst Rev. 2016 Sep 18;9(9):CD006992. doi: 10.1002/14651858.CD006992.pub2. Cochrane Database Syst Rev. 2016. PMID: 27640062 Free PMC article. Review. - Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis.
Hirst JA, Farmer AJ, Dyar A, Lung TW, Stevens RJ. Hirst JA, et al. Diabetologia. 2013 May;56(5):973-84. doi: 10.1007/s00125-013-2856-6. Epub 2013 Mar 15. Diabetologia. 2013. PMID: 23494446 Free PMC article. Review. - Prevention and treatment of type 2 diabetes: current role of lifestyle, natural product, and pharmacological interventions.
Hays NP, Galassetti PR, Coker RH. Hays NP, et al. Pharmacol Ther. 2008 May;118(2):181-91. doi: 10.1016/j.pharmthera.2008.02.003. Epub 2008 Mar 2. Pharmacol Ther. 2008. PMID: 18423879 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical